DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Metreleptin
Metreleptin
Chapter 7: Monogenic Forms of Diabetes
Myalept® (Metreleptin)
Putting Medications in Perspective for Chronic Weight Management
Amylin's $1 Billion Heavyweight Deal
September 2017 ~ Resource #330909
Nonobese, Nonketotic Childhood Onset Diabetes: Look for Lipodystrophies Partha P
Efficacy and Safety of Combination Treatment Versus Monotherapy in Obesity: a Meta-Analysis of Randomized Controlled Trials
2021 Formulary List of Covered Prescription Drugs
CDER List of Licensed Biological Products With
WHO Drug Information Vol
List Item Applications for New Human Medicines Under Evaluation by The
Insulin Glargine
Myalepta, INN-Metreleptin
Lists of Medicinal Products for Rare Diseases in Europe*
Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases
FDA Biologic Transition Plan Creates
2019 Annual Report
(CHMP) Agenda for the Meeting on 17-20 May 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
Top View
American Diabetes Association 2008 Annual Meeting
INN Working Document 05.179 Update December 2010
Medicines in Development for Diabetes
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
CDER List of Licensed Biological Products With
Glycomark Compendium of Evidence
Myalept (Metreleptin)
Quantum of Effectiveness Evidence in FDA's Approval of Orphan Drugs
Self-Administered Specialty Drug List
Metreleptin for Subcutaneous Injection 11.25 Mg “Shionogi” [Non-Proprietary Name] Metreleptin (Genetical Recombination) (JAN*) [Applicant] Shionogi & Co., Ltd
Myalept® (Metreleptin)
NYS Medicaid Fee-For-Service Preferred Drug List PREFERRED DRUG LIST – TABLE of CONTENTS I
Myalepta, INN-Metreleptin
Premium Value
Clinical Diabetes/Therapeutics
Glucagon-Like Peptide-1 Receptor Co-Agonists for Treating Metabolic Disease
Astrazeneca Sharps Disposal Plan
HHS Template for Reports, with Instructions
Volume III: Type 2 Diabetes and Obesity Therapeutics by David Thomas, CFA and Chad Wessel BIO INDUSTRY ANALYSIS About BIO
Pharmacotherapy for Weight Loss in Adults with Type 2 Diabetes: a Systematic Review of Randomised Controlled Trials
Eight Years on an Update on the National Severe Insulin Resistance Service
Advances in Medical Therapy for Weight Loss and the Weight-Centric Management of Type 2 Diabetes Mellitus
The Diagnosis and Management of Lipodystrophy Syndromes: a Multi-Society Practice Guideline
Mandatory Specialty Drug List
New Anti-Obesity Drugs on the Horizon
Evaluating the Need for an Orphan Drug Act in India by Comparing It with the US Orphan
Blue Cross Blue Shield of North Dakota Drug List Updates April 2018
Minutes of PRAC Meeting on 02-05 September 2019 for Publication
Self-Administered Medications List
Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
AHFS Pharmacologic-Therapeutic Classification System
Nhs-England-Drugs-List-V14.1.Pdf
Prior Authorization — Premium
MYALEPT (Metreleptin)
Minutes of the CHMP Meeting 12-15 October 2020
5.01.553 Myalept® (Metreleptin)
View the Specialty Pharmacy 1199 SEIU Drug List
The Birth of an Orphan Biosimilar Market Orphans Should Live Alone
The Leading Source of Diabetes Business News Baby Steps March/April 2011
Self-Administered Drugs Code List 2019
Metreleptin and Metformin Use in an Infant with Congenital Generalized Lipodystrophy Secondary to AGPAT2 Mutation
(12) United States Patent (10) Patent No.: US 8,895,033 B2 Houchin Et Al
Leptin Substitution in Patients with Lipodystrophy: Neural Correlates for Long-Term Success in the Normalization of Eating Behavior
Metreleptin As a Rescue Therapy in a Patient with a Novel Mutation for Familial Partial Lipodystrophy Type 3, Originally Presenting As Type 1 Diabetes
WO 2010/063124 Al
Restricted Use – Prior Approval Drug List
Exogenous Insulin Products
Myalept® (Metreleptin) Prior Authorization Program Summary
Late Breaking Abstracts
Pharmacological Approaches in the Treatment and Maintenance Of
2021 Medicaid Preapproval Criteria
Leptin's Hunger-Suppressing Effects Are Mediated by the Hypothalamic
List Item Applications for New Human
CNS-Targeting Pharmacological Interventions for the Metabolic Syndrome
125390Orig1s000
Metreleptin and Metformin Use in an Infant with Congenital Generalized Lipodystrophy Secondary to AGPAT2 Mutation
Lipodystrophy Could Give Metreleptin a New Lease of Life
Acquired Partial Lipoatrophy As Graft-Versus-Host Disease And